Jazz Pharmaceuticals plc Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31)
Jazz Pharmaceuticals plc (JAZZ) had Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) of $450.51 million as of 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesFairValueDisclosure · last filed 2013-05-07
- 2013-03-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $450.51M.
- 2012-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $387.20M.
- 2012-09-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $189.79M.
- 2012-06-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $154.54M.
| Period end | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) as first filed |
|---|---|---|
| 2013-03-31 | $450.51M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $387.20M 10-Q · filed 2013-05-07 | |
| 2012-09-30 | $189.79M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $154.54M 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $139.58M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $157.90M 10-K · filed 2013-02-26 | $124.59M 10-K · filed 2012-02-28 |
| 2010-12-31 | $25.05M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |